Floatz logo

Sapanisertib

Pancreatic Neuroendocrine Tumor G1

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Pancreatic Neuroendocrine Tumor G1 cohort.

Asset / SponsorPhaseRating
Oxodotreotide
Vanderbilt-Ingram Cancer Center
Phase 4BB
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-
National Cancer Institute (NCI)
Phase 2B
Everolimus
AC Camargo Cancer Center
Phase 2B
[212pb] vmt-α-net
David Bushnell
Early Phase 1C

Same molecule, other indications

Sapanisertib is also rated in:

non-small cell lung carcinomaActive
BB
Indicative · Phase 2
65 / 100
View asset →
pancreatic neuroendocrine tumorDormant
B
Indicative · Phase 2
61 / 100
View asset →
plasma cell myelomaActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →